Applications of molecular detection of lung cancer in developing countries

Abstract

Abstract:The era of personalized medicine of nonsmall cell lung cancer has arrived. Gene detecrion is part of the daily clinical decision, at least for patients with adenocarcinoma. Access to those tests is still very limited in the developing world: quality control, reimbursement/cost and widespread access. Because of the differences in the national conditions of developing countries, strategies certainly vary from country to country. Molecular epidemiology data generated by developing countries, as well as the use of their emerging scientific and technologic capacities to generate and validate novel biomarkers and diagnostic kits, will certainly contribute to better treatment of patients with lung cancer worldwide.

Key words:Carcinoma, non-small-cell lung,Genes,Developing countries

Jia Youchao, Shang Yanhong, Zang Aimin. Applications of molecular detection of lung cancer in developing countries[J]. Journal of International Oncology, 2014, 41(1): 47-49.

References

［1］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012［J］. CA Cancer J Clin, 2012, 62:1029. ［2］ McCloskey P, Balduyck B, Van Schil PE, et al. Radical treatment of nonsmall cell lung cancer during the last 5 years［J］. Eur J Cancer, 2013, 49(7):15551564. ［3］ Hennon MW, Yendamuri S. Advances in lung cancer surgery［J］. J Carcinog, 2012, 11:21. ［4］ National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lungcancer mortality with lowdose computed tomographic screening［J］. N Engl J Med, 2011, 365(5):395409. ［5］ Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma［J］. Genome Res, 2012, 22(11):21092119. ［6］ Azzoli CG, Baker S Jr, Temin S, et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage Ⅳ nonsmallcell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2010, 13(3):171189. ［7］ Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer［J］. J Clin Oncol, 2007, 25(1):118145. ［8］ Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008［J］. Int J cancer, 2010, 127(12):28932917. ［9］ Atherly AJ, Camidge DR. The costeffectiveness of screening lung cancer patients for targeted drug sensitivity markers［J］. Br J Cancer, 2012, 106(6):11001116. ［10］ Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never smokersa review［J］. Eur J Cancer, 2012, 48(9):12991311. ［11］周航, 梅同华, 赵麟丰, 等. 肺癌分子靶向治疗的现状与进展. 国际肿瘤学杂志, 2007, 34(7):493496. ［12］ Galanter JM, FernandezLopez JC, Gignoux CR, et al. Development of a panel of genomewide ancestry informative markers to study admixture throughout the Americas［J］. PLoS Genet, 2012, 8(3):e1002554. ［13］ Reich D, Patterson N, Campbell D, et al. Reconstructing Native American population history［J］. Nature, 2012, 488(7411):370374. ［14］ Bacchi CE, Ciol H, Queiroga EM, et al. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients［J］. Clinics (Sao Paulo), 2012, 67(5):419424. ［15］ Pena SD, Di Pietro G, FuchshuberMoraes M, et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected［J］. PLoS One, 2011, 6(2):e17063. ［16］ Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers［J］. Nature, 2012 489(7417):519525.

[1]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[2]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie.Research progress of myeloid-derived suppressor cells in tumor angiogenesis[J]. Journal of International Oncology, 2024, 51(1): 50-54.
[3]	Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui.Role of ABRACL in the occurrence and development of malignant tumors[J]. Journal of International Oncology, 2023, 50(9): 544-547.
[4]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[5]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei.Current status of research on exosomes in malignancies[J]. Journal of International Oncology, 2023, 50(8): 484-488.
[6]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[7]	Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757.
[8]	Li Lixi, Wen Tingyu, Guan Xiuwen, Zhai Jingtong, Ma Fei.Genetic susceptibility genes and clinical features of early-onset breast cancer[J]. Journal of International Oncology, 2022, 49(4): 206-209.
[9]	Yu Jiaojiao, Wang Jun, Wang Likang, Yao Nan.Advances in the amplification of HER2 in metastatic colorectal cancer[J]. Journal of International Oncology, 2021, 48(4): 246-249.
[10]	Zheng Jing, Yao Sheng, Shen Wenjie, Sun Zhijia, Zhao Hui, Fu Yan, Gao Ke, Du Nan.Clinical study of intraperitoneal infusion of bevacizumab combined with albumin paclitaxel and carboplatin in carcinomatous peritoneal adhesion from ovarian cancer[J]. Journal of International Oncology, 2021, 48(11): 660-665.
[11]	Ren Meng, Gao Yan, Chen Qi, Yue Wentao.Application of keratins in cancer diagnosis and prognosis[J]. Journal of International Oncology, 2020, 47(6): 360-363.
[12]	Zou Wenjing, He Shuixiang, Liu Dan, Li Xu.Screening differential genes and prognostic analysis of gastric cancer based on TCGA database[J]. Journal of International Oncology, 2020, 47(4): 211-216.
[13]	Zhao Chuanxi, Zhu Tingting, Liu Mingguo, Cao Lili.Advances of Krüppel-like factors in hepatocellular carcinoma[J]. Journal of International Oncology, 2020, 47(2): 119-122.
[14]	Song Mingze, Cheng Yiming, Li Gang, Wang Zhenming, Li Shirong.Value of P16/Ki-67 double staining detection in screening cervical cancer and precancerous lesions[J]. Journal of International Oncology, 2020, 47(11): 675-681.
[15]	Zhang Yuan, Sun Lichao.Advances of homeobox gene MEOX1 in tumors[J]. Journal of International Oncology, 2019, 46(5): 278-280.